Hims Adds Lilly's Zepbound to Platform, Plans New Peptides After Guidance Cut
HIMS sits 38% above its 52-week low of $13.74 on elevated volume (5.0× avg).
Summary
Hims agreed to offer Eli Lilly's Zepbound and Foundayo weight-loss treatments through its platform, with prescriptions available after a provider consultation. That is a notable shift for a company whose weight-loss business has been built on compounded GLP-1s, which face FDA warnings and an HHS interim access policy still under White House review. Separately, Hims plans November launches of glutathione, sermorelin and NAD+ products, with BPC-157 and TB-500 to follow subject to federal policy, and expects limited revenue from them this year. The backdrop is a rough quarter: Q3 revenue of $890.4 million rose 49% but missed estimates, the company posted a $33 million net loss, and it cut full-year EBITDA guidance, sending shares down more than 15%. The Lilly tie-up gives the platform a branded option as compounded supply rules tighten, but the new peptide lineup carries regulatory risk and won't move 2026 numbers.
At the time of this announcement, HIMS was trading at $19.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $4.5B. The 52-week trading range was $13.74 to $42.70. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.